Passing a federal law that trims drug industry profits on companies’ top products by between 15% and 25% would lead to about 2 fewer drugs (-0.5%) being introduced in the U.S. in the law’s first decade, 23 fewer (-5%) in the second, and 34 fewer (-8%), in the third, congressional budget analysts say.
Congress Tweaks its Projection of Drug Pricing Bills’ Impact on Rx Drug Pipeline
